Closings of Series C Financing Round

San Francisco, May 31, 2023 - Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and other diseases, announced closings of its Series C financing round. 

This financing and closings includes existing shareholders as well as new undisclosed investors. The current proceeds will be used to complete the global pivotal Phase 3 study for Recardio’s lead therapeutic candidate, Dutogliptin, which is being developed for the treatment of acute myocardial infarction (AMI), commonly known as heart attack. The financing will also support the therapeutic and regional expansion of Recardio.

“The coming years will be exciting for Recardio as we are starting our global pivotal Phase 3 trial with Dutogliptin in AMI, one of the most promising indications from our cardiovascular platform technology” said Dr. Roman Schenk, Recardio’s founder, President and Executive Chairman.

Recardio’s non-invasive regenerative approach can potentially play a significant role in improving the survival rate and quality of life for patients who experience a heart attack, as well as in various other cardiovascular diseases.

About Recardio

Recardio Inc. is a late clinical-stage life science company focused on developing therapies for cardiovascular and other diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines critical for cardiac regeneration, resulting in healing cardiac tissue after an injury.

Recardio has received FDA and EMA clearance for a global pivotal phase III HEAL-MI clinical trial in acute myocardial infarction.  This trial is planned to initiate in 2025 and will serve as the basis to apply for market authorization in major global markets. Recardio plans to fully develop its therapeutic platform for patients with various cardiovascular diseases. The company is headquartered in San Francisco, California, with operations in both the US and Europe.

For more information, visit: www.recardio.eu or contact pr@recardio.eu